Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVOGet Free Report) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

Shares of NASDAQ APVO opened at $0.30 on Tuesday. The firm’s 50-day moving average price is $0.69 and its two-hundred day moving average price is $3.68. Aptevo Therapeutics has a 52-week low of $0.28 and a 52-week high of $80.96.

Aptevo Therapeutics (NASDAQ:APVOGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($14.10) by $4.15. On average, analysts predict that Aptevo Therapeutics will post -8.86 EPS for the current year.

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Further Reading

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.